MedTrace Logo

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

NCT01804543 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-03-05

No results posted yet for this study

Summary

Evaluation of use of ranolazine in patients with stable heart pain with cardiac magnetic resonance imaging (CMRI) and phosphorous-31 magnetic resonance spectroscopy (31P MRS). Subsequent testing using these modalities will show improved oxygen to the heart muscle.

Conditions

Interventions

DRUG

Ranolazine

ranolazine 500 mg, then 1000 mg twice a day

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Westside Medical Associates of Los Angeles

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01804543 on ClinicalTrials.gov